Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Moxifloxacin Alternative Formulation 0.5% · 2 trials · 1 indication
Clinical cure was attained if the sum of the 2 cardinal ocular signs of bacterial conjunctivitis (bulbar conjunctival injection and conjunctival discharge/exudate) was zero (ie, normal or absent) 12-48 hours after the last dose. Clinical cure was reported as a percentage. Only one eye (study eye) contributed to the analysis.
| Arm | Type | Description |
|---|---|---|
| Moxifloxacin AF | EXPERIMENTAL | Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, 1 drop in each eye twice daily for 3 days |
| Vehicle | PLACEBO_COMPARATOR | Moxifloxacin AF vehicle, 1 drop in each eye twice daily for 3 days |
| Moxifloxacin | EXPERIMENTAL | - |
| VIGAMOX | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5% | DRUG | Eye drops |
| Moxifloxacin AF Vehicle | OTHER | Inactive ingredients used as a placebo for masking purposes |
| Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5% | DRUG | 1 drop into the conjunctival sac of both eyes 3 times a day for 3 days |
| Moxifloxacin hydrochloride ophthalmic solution 0.5% as base | DRUG | 1 drop into the conjunctival sac of both eyes 3 times a day for 3 days |
Inclusion Criteria: * Diagnosed with bacterial conjunctivitis in 1 or both eyes; * Able to understand and sign an informed consent form. If subject is \<18 years of age, the informed consent must be understood and signed by the subject's legally authorized representative; * Agrees to comply with th...